Warren blasts Gottlieb's jump to Pfizer, but ex-FDA chief says he's 'proud'

Elizabeth Warren
Shortly after leaving the FDA, former commissioner Scott Gottlieb is now a board member at Pfizer. (Edward Kimmel/CC BY-SA 2.0)

Scott Gottlieb and Pfizer surely knew critics would challenge the former FDA commissioner’s decision to join the pharma giant's board—less than three months after his departure from the agency, no less.

And at least one high-profile lawmaker is doing just that, as Sen. Elizabeth Warren called on Gottlieb to reconsider.

The move "smacks of corruption," Warren wrote in a letter following the announcement. Gottlieb will join a company that has “billions of dollars at stake in the decisions made by the agency you used to head and the employees you used to lead," Warren wrote.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

Such a fast move from government to industry “makes the American people rightfully cynical and distrustful about whether high-level Trump Administration officials are working for them, or for their future corporate employers,” she added. 

The move could prove to be lucrative for Gottlieb as Pfizer compensates its board members well, Warren pointed out. Last year, the company paid directors $335,000 in cash and stock.

RELATED: Cue the ‘revolving door’ criticism: Former FDA commissioner Gottlieb joins Pfizer’s board 

Gottlieb took to CNBC to defend the decision. He said in an interview with the network that he’s “proud” of the relationship. He worked in the life sciences industry before he joined the FDA, and now has returned to similar roles, he added.

“I feel very confident about my record at the agency and the fact that I called balls and strikes and acted in the interest of public health,” Gottlieb said. 

Gottlieb announced his FDA resignation in March and served until the beginning of April. He started with the agency in May 2017. In stepping down, he said he wanted to spend more time with his family.  

RELATED: FDA chief Scott Gottlieb steps down, leaving pet projects behind 

At the FDA, he was popular for taking an industry-friendly stance on numerous issues involving innovation and for fighting high drug prices.

Suggested Articles

For just the second time, the DOJ indicted an opioid distributor for its role in illegally pushing pills at the height of the addiction epidemic.

Bristol-Myers Squibb is out to expand the pool of colorectal cancer patients it can treat with Opdivo—and it’s bringing in Bayer to help.

When AstraZeneca sold its Avlon, England plant in 2016, it thought its liabilities were over. Former employees said the drugmaker broke its promises.